Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ACLY | P53396 | 2/20 | 0.43 |
| ▸ | METAP2 | P50579 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032987 | 0.81 | LMNA (0.45) | KMT2AACLYMETAP2SMN1; SMN2HSD17B10 | |
| Hydrochloric Acid SCHEMBL9649707 | 0.80 | LMNA (0.44) | KMT2AACLYMETAP2SMN1; SMN2HSD17B10 | |
| SCHEMBL3529403 | 0.79 | KMT2A (0.55) | CCR2KEAP1NFE2L2KMT2AMCL1 | |
| SCHEMBL3237040 | 0.79 | KMT2A (0.44) | NR3C1CCR2KEAP1NFE2L2KMT2A | |
| SCHEMBL13715485 | 0.77 | KDM4E (0.58) | KMT2AKDM4ESMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL5226243 | 0.77 | KEAP1 (0.61) | NR3C1CCR2KEAP1NFE2L2KMT2A | |
| SCHEMBL30100431 | 0.75 | ACLY (0.66) | CCR2KMT2AACLYMETAP2KDM4E | |
| SCHEMBL219920 | 0.75 | ACLY (0.66) | CCR2KMT2AACLYMETAP2KDM4E | |
| SCHEMBL7556603 | 0.75 | CCR2 (0.63) | CCR2KMT2AACLYKDM4ESMN1; SMN2 | |
| SCHEMBL222213 | 0.73 | METAP2 (0.68) | KMT2AACLYMETAP2MCL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | NR3C1 500/4885CCR2 289/4885KEAP1 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.